Key result
Amiodarone-related thyroid dysfunction in HF linked to ~30% higher 1-year risk of HF hospitalization or death.
Why the study?
Amiodarone increases the risk of thyroid dysfunction, but the prognostic significance of this complication in patients with heart failure remains uncertain.
Does amiodarone-related thyroid dysfunction increase the risk of HF hospitalization or death in patients with heart failure?
Population
2953 cases and 5857 matched controls from a nationwide cohort of 21,947 HF patients initiating amiodarone
Comparison
Amiodarone-related thyroid dysfunction vs matched controls without thyroid dysfunction
Design
Nationwide nested case-control study
Follow-up
1 year
Authors
Loading...
May warrant closer thyroid monitoring in amiodarone-treated HF; leaves open causality and need for prospective trials.
Case-Control (n=8,810)
Yes
Does amiodarone-related thyroid dysfunction increase the risk of HF hospitalization or death in patients with heart failure?
Effect estimate: HR 1.30 (95% CI 1.21-1.40)
Absolute Event Rate: 39% vs 31%
In patients with heart failure treated with amiodarone, the development of thyroid dysfunction is associated with a 30% increased risk of HF hospitalization or death within 1 year.
Kristensen et al. (2026) conducted a case-control in Heart failure (n=8,810). Amiodarone-related thyroid dysfunction vs. Matched controls without thyroid dysfunction was evaluated on Composite of HF hospitalization and death within 1 year from onset of thyroid dysfunction (HR 1.30, 95% CI 1.21-1.40). Amiodarone-related new-onset thyroid dysfunction in heart failure patients was associated with a higher risk of HF hospitalization or death at 1 year (HR 1.30; 95% CI 1.21-1.40).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: